Sino-US biotech Sirius Therapeutics has announced its pursuit of Investigational New Drug (IND) approval in Australia to conduct a first-in-human clinical trial for its pipeline candidate, SRSD107. This next-generation small interfering RNA (siRNA) therapeutic is under development for the treatment of thromboembolic disorders and targets coagulation factor XI (FXI). Notably, SRSD107 is Sirius’s inaugural compound to reach the clinical trial stage.
Sirius Therapeutics: A Cross-Continental Biotechnology Venture
Established in 2021, Sirius Therapeutics boasts an innovative discovery center in San Diego, US, and a translational medicine center in Shanghai, China. The company’s SRSD107 has reportedly demonstrated robust preclinical data, highlighting exceptional durability and a favorable safety profile. This positions SRSD107 as a potential best- and first-in-class FXI siRNA therapeutic.- Flcube.com
